Research programme: cancer therapeutics - Merck/SCYNEXIS
Latest Information Update: 29 Mar 2010
At a glance
- Originator Merck & Co; SCYNEXIS
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Research Cancer
Most Recent Events
- 29 Mar 2010 Preclinical development is ongoing in USA